Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel

• DOI: 10.1136/neurintsurg-2020-016994
• Publication Date: 2021-02-25T18:25:42Z
• Authors: Saeko Higashiguchi; Akiyo Sadato; Ichiro Nakahara; Shoji Matsumoto; Motoharu Hayakawa; Kazuhide Adachi; Akiko Hasebe; Yoshio Suyama; Tatsuo Omi; Kei Yamashiro; Akira Wakako; Takuma Ishihara; Yushi Kawazoe; Tadashi Kumai; Jun Tanabe; Kenichiro Suyama; Sadayoshi Watanabe; Takeya Suzuki; Yuichi Hirose
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Aspirin; Clinical Neurology; Humans; Intracranial Aneurysm; Prasugrel Hydrochloride; Platelet Aggregation Inhibitors; Retrospective Studies; 3. Good health

BackgroundThromboembolic complications (TECs) are frequent during the endovascular treatment of unruptured aneurysms. To prevent TECs, dual antiplatelet therapy using aspirin and clopidogrel is recommended for the perioperative period. In patients with a poor response, clopidogrel is a risk factor for TECs. To prevent TECs, our study assessed the stratified use of prasugrel.MethodsPatients who underwent endovascular therapy for unruptured cerebral aneurysms from April 2017 to August 2019 were enrolled in this clinical study and given premedication with aspirin and clopidogrel for 2 weeks prior to the procedure. P2Y12 reaction units (PRU) were measured using the VerifyNow assay on the day before the procedure (tailored group). In subgroups with PRU <240, the clopidogrel dose was maintained (CPG subgroup). In subgroups with PRU ≥240, clopidogrel was changed to prasugrel (PSG subgroup). We compared the occurrence of TECs with retrospective consecutive cases from January 2015 to March 2017 without PRU assessments (non-tailored group). The frequency of TECs within 30 days was assessed as the primary endpoint.ResultsThe tailored and non-tailored groups comprised 167 and 50 patients, respectively. TECs occurred in 11 (6.6%) and 8 (16%) patients in the tailored and non-tailored groups (P=0.048), respectively. The HR for TECs was significantly reduced in the tailored group (HR 0.3, 95% CI 0.11 to 0.81); P=0.017) compared with the non-tailored group.ConclusionThe results suggest that tailored dual antiplatelet therapy medication with PRU significantly reduces the frequency of TECs without increasing hemorrhagic complications.